ClinicalTrials.Veeva

Menu
T

Texas Diabetes & Endocrinology | Austin, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Semaglutide
EDP-305
Insulin icodec
Bococizumab
ACT-132577
Semagludtide
Aprocitentan
CNP-103
Androderm
BELVIQ

Parent organization

This site is a part of Texas Diabetes & Endocrinology

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 30 total trials

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide (AMAZE 7)

The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treat...

Begins enrollment in 2 months
Overweight
Obesity
Drug: Placebo (matched to zenagamtide)
Drug: Semaglutide

This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight i...

Active, not recruiting
Obesity
Drug: Semaglutide
Drug: Placebo
Locations recently updated

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investi...

Enrolling
Diabetes Mellitus, Type 1
Drug: Insulin glargine
Drug: Insulin icodec

This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple a...

Enrolling
Type 1 Diabetes Patients
Type 1 Diabetes Mellitus
Drug: CNP-103
Drug: Placebo

The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disp...

Enrolling
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Device: MiniMed™ NMX8-AID System with DS5™/Simplera Sync™

The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in...

Active, not recruiting
Diabetes Mellitus, Type 1
Drug: Lispro
Drug: HDV-Lispro

A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titr...

Enrolling
Type 2 Diabetes (T2D)
Type 1 Diabetes (T1D)
Device: MODI Algorithm

Trial sponsors

Novo Nordisk logo
Enanta Pharmaceuticals logo
Pfizer logo
M
Allergan logo
A
C
D
D
Eisai logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems